Evidence map›Paper›PMID 32954290›Full record

ArticleBrain communications2020

Putaminal diffusion tensor imaging measures predict disease severity across human prion diseases.

Harpreet Hyare, Enrico De Vita, Marie-Claire Porter, Ivor Simpson, Gerard Ridgway, Jessica Lowe, Andrew Thompson, Chris Carswell, Sebastien Ourselin, Marc Modat and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Harpreet HyareMRC Prion Unit at UCL, Institute of Prion Diseases, London SE1 7EH, UK.ORCID 0000-0002-4672-3349
Enrico De VitaDepartment of Biomedical Engineering, Centre for Medical Engineering, School of Biomedical Engineering & Imaging Sciences, King's College London, King's Health Partners, St Thomas' Hospital, London SE1 7EH, UK.
Marie-Claire PorterMRC Prion Unit at UCL, Institute of Prion Diseases, London SE1 7EH, UK.
Ivor SimpsonUCL Institute of Neurology, London, UK.
Gerard RidgwayUCL Institute of Neurology, London, UK.
Jessica LoweMRC Prion Unit at UCL, Institute of Prion Diseases, London SE1 7EH, UK.
Andrew ThompsonMRC Prion Unit at UCL, Institute of Prion Diseases, London SE1 7EH, UK.
Chris CarswellMRC Prion Unit at UCL, Institute of Prion Diseases, London SE1 7EH, UK.
Sebastien OurselinDepartment of Biomedical Engineering, Centre for Medical Engineering, School of Biomedical Engineering & Imaging Sciences, King's College London, King's Health Partners, St Thomas' Hospital, London SE1 7EH, UK.
Marc ModatDepartment of Biomedical Engineering, Centre for Medical Engineering, School of Biomedical Engineering & Imaging Sciences, King's College London, King's Health Partners, St Thomas' Hospital, London SE1 7EH, UK.
Liane Dos Santos CanasCentre for Medical Image Computing, UCL, London, UK.
Diana CaineMRC Prion Unit at UCL, Institute of Prion Diseases, London SE1 7EH, UK.
Zoe FoxEducation Unit, UCL Institute of Neurology, London, UK.
Peter RudgeMRC Prion Unit at UCL, Institute of Prion Diseases, London SE1 7EH, UK.
John CollingeMRC Prion Unit at UCL, Institute of Prion Diseases, London SE1 7EH, UK.
Simon MeadMRC Prion Unit at UCL, Institute of Prion Diseases, London SE1 7EH, UK.
John S ThorntonUCL Institute of Neurology, London, UK.
MRC Prion Unit · GBUniversity College London · GBSt Thomas' Hospital · GB

Funding

Medical Research Council G0400713Medical Research Council MC_U123160651Medical Research Council MC_U123160657Medical Research Council MC_UU_00024/1Medical Research Council MC_UU_00024/9
6 · The paper itself

Abstract

Therapeutic trials of disease-modifying agents in neurodegenerative disease typically require several hundred participants and long durations for clinical endpoints. Trials of this size are not feasible for prion diseases, rare dementia disorders associated with misfolding of prion protein. In this situation, biomarkers are particularly helpful. On diagnostic imaging, prion diseases demonstrate characteristic brain signal abnormalities on diffusion-weighted MRI. The aim of this study was to determine whether cerebral water diffusivity could be a quantitative imaging biomarker of disease severity. We hypothesized that the basal ganglia were most likely to demonstrate functionally relevant changes in diffusivity. Seventy-one subjects (37 patients and 34 controls) of whom 47 underwent serial scanning (23 patients and 24 controls) were recruited as part of the UK National Prion Monitoring Cohort. All patients underwent neurological assessment with the Medical Research Council Scale, a functionally orientated measure of prion disease severity, and diffusion tensor imaging. Voxel-based morphometry, voxel-based analysis of diffusion tensor imaging and regions of interest analyses were performed. A significant voxel-wise correlation of decreased Medical Research Council Scale score and decreased mean, radial and axial diffusivities in the putamen bilaterally was observed (

Indexed as

CJDMRIprion

Identifiers

PMID32954290
PMCPMC7425333
OpenAlexW3015880989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.